Laboratory Animal and Comparative Medicine
WANG Lu1(
)(
), WANG Qingjie2, YANG Chunhong1, ZHANG Yijian1(
)(
)
Online:2026-06-11
Contact:
ZHANG Yijian
CLC Number:
WANG Lu,WANG Qingjie,YANG Chunhong,et al. The Application of New Approach Methodologies in the Biomedical Field and Its Implementation of "3R" Principle[J]. Laboratory Animal and Comparative Medicine. DOI: 10.12300/j.issn.1674-5817.2025.164.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.slarc.org.cn/dwyx/EN/10.12300/j.issn.1674-5817.2025.164
3R原则 3R principle | 核心目标 Core objective | 典型案例 Representative case | 核心价值 Core value proposition |
|---|---|---|---|
替代 Replacement | 从 “动物依赖” 到 “人体仿生”, 用低等级动物代替高等级动物,或用非动物模型完全取代,实现零动物伤害 | RhE 模型:体外培养人角质形成细胞,模拟皮肤刺激反应,已纳入 OECD TG FDA 2025年允许类器官、器官芯片数据替代单抗药物动物实验数据,并计划扩展至其它领域 | 科学:避免物种差异,提升人体反应预测准确性 伦理:从根源减少实验动物痛苦,实现动物福利核心目标 |
减少 Reduction | 从 “大量筛选” 到 “精准预筛”,在保证科学性前提下减少实验动物使用数量 | EPA ToxCast 项目:利用高通量筛选和计算毒理学筛选化合物毒性,减少了毒理学测试中实验动物使用 FDA允许在药物开发过程中使用非动物替代方法进行毒理学测试,不再强制要求动物测试。 | 科学:提升筛选效率与实验设计精准度,减少重复试验 伦理:降低动物使用量,减少动物承受痛苦的总量,符合 “最少动物获有效数据” 原则 |
优化 Refinement | 从 “被动观察” 到 “主动减痛”,最大限度减轻实验动物疼痛与压力,提升福利水平 | Darwish 等:曲非奈肽 PBPK 模型预测肾损患者剂量,为动物实验设定精准用药范围 FDA/EMA:批准肾损伤生物标志物作为动物实验提前终止依据,避免终末期肾衰竭痛苦 | 科学:减少动物应激对数据的干扰,提升实验可靠性与可重复性 伦理:缩短动物痛苦周期,降低应激与不适程度,保障动物生命尊严 |
Table 1 The implementation of the "3R" principle through New approach methodologies
3R原则 3R principle | 核心目标 Core objective | 典型案例 Representative case | 核心价值 Core value proposition |
|---|---|---|---|
替代 Replacement | 从 “动物依赖” 到 “人体仿生”, 用低等级动物代替高等级动物,或用非动物模型完全取代,实现零动物伤害 | RhE 模型:体外培养人角质形成细胞,模拟皮肤刺激反应,已纳入 OECD TG FDA 2025年允许类器官、器官芯片数据替代单抗药物动物实验数据,并计划扩展至其它领域 | 科学:避免物种差异,提升人体反应预测准确性 伦理:从根源减少实验动物痛苦,实现动物福利核心目标 |
减少 Reduction | 从 “大量筛选” 到 “精准预筛”,在保证科学性前提下减少实验动物使用数量 | EPA ToxCast 项目:利用高通量筛选和计算毒理学筛选化合物毒性,减少了毒理学测试中实验动物使用 FDA允许在药物开发过程中使用非动物替代方法进行毒理学测试,不再强制要求动物测试。 | 科学:提升筛选效率与实验设计精准度,减少重复试验 伦理:降低动物使用量,减少动物承受痛苦的总量,符合 “最少动物获有效数据” 原则 |
优化 Refinement | 从 “被动观察” 到 “主动减痛”,最大限度减轻实验动物疼痛与压力,提升福利水平 | Darwish 等:曲非奈肽 PBPK 模型预测肾损患者剂量,为动物实验设定精准用药范围 FDA/EMA:批准肾损伤生物标志物作为动物实验提前终止依据,避免终末期肾衰竭痛苦 | 科学:减少动物应激对数据的干扰,提升实验可靠性与可重复性 伦理:缩短动物痛苦周期,降低应激与不适程度,保障动物生命尊严 |
| [1] | 王贵平, 周正宇. 关于我国实验动物福利伦理的思考及建议[J]. 中国实验动物学报, 2023, 31(5): 683-689. DOI: 10.3969/j.issn.1005-4847.2023.05.016 . |
| WANG G P, ZHOU Z Y. Reflections and suggestions on the ethics and welfare of laboratory animals in China[J]. Acta Lab Anim Sci Sin, 2023, 31(5): 683-689. DOI: 10.3969/j.issn.1005-4847.2023.05.016 . | |
| [2] | SMITH M L, ASADA N, MALENKA R C. Anterior cingulate inputs to nucleus accumbens control the social transfer of pain and analgesia[J]. Science, 2021, 371(6525): 153-159. DOI: 10.1126/science.abe3040 . |
| [3] | FANG W, LI J R, QI G Y, et al. Statistical inference of body representation in the macaque brain[J]. Proc Natl Acad Sci U S A, 2019, 116(40): 20151-20157. DOI: 10.1073/pnas.1902334116 . |
| [4] | RUSSELL W M S, BURCH R L. The principles of humane experimental technique[M]. London: Methuen, 1959. |
| [5] | SEWELL F, ALEXANDER-WHITE C, BRESCIA S, et al. New approach methodologies (NAMs): identifying and overcoming hurdles to accelerated adoption[J]. Toxicol Res, 2024, 13(2): tfae044. DOI: 10.1093/toxres/tfae044 . |
| [6] | YANG S Q, HU H J, KUNG H, et al. Organoids: The current status and biomedical applications[J]. MedComm, 2023, 4(3): e274. DOI: 10.1002/mco2.274 . |
| [7] | AHAMMED B, KALANGI S K. A decade of organoid research: progress and challenges in the field of organoid technology[J]. ACS Omega, 2024, 9(28): 30087-30096. DOI: 10.1021/acsomega.4c03683 . |
| [8] | WILSON H V. A new method by which sponges may be artificially reared[J]. Science, 1907, 25(649): 912-915. DOI: 10.1126/science.25.649.912 . |
| [9] | SATO T, VRIES R G, SNIPPERT H J, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche[J]. Nature, 2009, 459(7244): 262-265. DOI: 10.1038/nature07935 . |
| [10] | CORRÒ C, NOVELLASDEMUNT L, LI V S W. A brief history of organoids[J]. Am J Physiol Cell Physiol, 2020, 319(1): C151-C165. DOI: 10.1152/ajpcell.00120.2020 . |
| [11] | ZHAO Y M, LANDAU S, OKHOVATIAN S, et al. Integrating organoids and organ-on-a-chip devices[J]. Nat Rev Bioeng, 2024, 2(7): 588-608. DOI: 10.1038/s44222-024-00207-z . |
| [12] | HUANG M S, CHRISTAKOPOULOS F, ROTH J G, et al. Organoid bioprinting: from cells to functional tissues[J]. Nat Rev Bioeng, 2025, 3(2): 126-142. DOI: 10.1038/s44222-024-00268-0 . |
| [13] | CERNECKIS J, BU G J, SHI Y H. Pushing the boundaries of brain organoids to study Alzheimer's disease[J]. Trends Mol Med, 2023, 29(8): 659-672. DOI: 10.1016/j.molmed.2023.05.007 . |
| [14] | TIWARI S K, RANA T M. Generation of 3D lung organoids from human induced pluripotent stem cells for modeling of lung development and viral infection[J]. Heliyon, 2023, 9(9): e19601. DOI: 10.1016/j.heliyon.2023.e19601 . |
| [15] | TAN S Y, DING Y, WANG W, et al. Development of an AI model for DILI-level prediction using liver organoid brightfield images[J]. Commun Biol, 2025, 8(1): 886. DOI: 10.1038/s42003-025-08205-6 . |
| [16] | TANAKA J, MISHIMA K. Generation of salivary gland organoids from mouse embryonic stem cells[M]//Stem Cell Assays. New York, NY: Springer US, 2022: 247-255. DOI: 10.1007/978-1-0716-1979-7_16 . |
| [17] | WANG H M, ZHANG C Y, PENG K C, et al. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study[J]. Cell Rep Med, 2023, 4(2): 100911. DOI: 10.1016/j.xcrm.2022.100911 . |
| [18] | CAO U M N, ZHANG Y L, CHEN J L, et al. Microfluidic organ-on-A-chip: a guide to biomaterial choice and fabrication[J]. Int J Mol Sci, 2023, 24(4): 3232. DOI: 10.3390/ijms24043232 . |
| [19] | HUH D, MATTHEWS B D, MAMMOTO A, et al. Reconstituting organ-level lung functions on a chip[J]. Science, 2010, 328(5986): 1662-1668. DOI: 10.1126/science.1188302 . |
| [20] | KIM H J, HUH D, HAMILTON G, et al. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow[J]. Lab Chip, 2012, 12(12): 2165-2174. DOI: 10.1039/c2lc40074j . |
| [21] | LI B, TANG Y J, HUANG Z Y, et al. Synergistic innovation in organ-on-a-chip and organoid technologies: Reshaping the future of disease modeling, drug development and precision medicine[J]. Protein Cell, 2025: pwaf058. DOI: 10.1093/procel/pwaf058 . |
| [22] | HUANG Q H, YANG T H, SONG Y P, et al. A three-dimensional (3D) liver–kidney on a chip with a biomimicking circulating system for drug safety evaluation[J]. Lab Chip, 2024, 24(6): 1715-1726. |
| [23] | TAO T T, DENG P W, WANG Y Q, et al. Microengineered multi-organoid system from hiPSCs to recapitulate human liver-islet axis in normal and type 2 diabetes[J]. Adv Sci, 2022, 9(5): e2103495. DOI: 10.1002/advs.202103495 . |
| [24] | SUNILDUTT N, PARIHAR P, CHETHIKKATTUVELI SALIH A R, et al. Revolutionizing drug development: harnessing the potential of organ-on-chip technology for disease modeling and drug discovery[J]. Front Pharmacol, 2023, 14: 1139229. DOI: 10.3389/fphar.2023.1139229 . |
| [25] | BALACHANDER G M, NG I C, PAI R R, et al. LEADS - a comprehensive human liver-on-a-chip for non-alcoholic steatohepatitis (NASH) drug testing[J]. Lab Chip, 2025, 25(14): 3444-3466. DOI: 10.1039/d5lc00221d . |
| [26] | ZHANG T Y, YANG S, GE Y L, et al. Unveiling the heart's hidden enemy: dynamic insights into polystyrene nanoplastic-induced cardiotoxicity based on cardiac organoid-on-a-chip[J]. ACS Nano, 2024, 18(45): 31569-31585. DOI: 10.1021/acsnano.4c13262 . |
| [27] | RONALDSON-BOUCHARD K, TELES D, YEAGER K, et al. A multi-organ chip with matured tissue niches linked by vascular flow[J]. Nat Biomed Eng, 2022, 6(4): 351-371. DOI: 10.1038/s41551-022-00882-6 . |
| [28] | LEVATO R, DUDARYEVA O, GARCIAMENDEZ-MIJARES C E, et al. Light-based vat-polymerization bioprinting[J]. Nat Rev Methods Primers, 2023, 3: 47. DOI: 10.1038/s43586-023-00231-0 DOI: 10.1038/s43586-023-00231-0 . |
| [29] | MIRONOV V, BOLAND T, TRUSK T, et al. Organ printing: computer-aided jet-based 3D tissue engineering[J]. Trends Biotechnol, 2003, 21(4): 157-161. DOI: 10.1016/S0167-7799(03)00033-7 . |
| [30] | SAFHI A Y. Three-dimensional (3D) printing in cancer therapy and diagnostics: current status and future perspectives[J]. Pharmaceuticals, 2022, 15(6): 678. DOI: 10.3390/ph15060678 . |
| [31] | 胡敏, 董乐轩, 高怡, 等. 生物3D打印研究及与临床前动物模型的交叉应用展望[J]. 实验动物与比较医学, 2025, 45(3): 318-330. DOI: 10.12300/j.issn.1674-5817.2024.193 . |
| HU M, DONG L X, GAO Y, et al. Prospects for 3D bioprinting research and transdisciplinary application to preclinical animal models[J]. Lab Anim Comp Med, 2025, 45(3): 318-330. DOI: 10.12300/j.issn.1674-5817.2024.193 . | |
| [32] | GONZÁLEZ-CALLEJO P, VÁZQUEZ-ARISTIZABAL P, GARCÍA-ASTRAIN C, et al. 3D bioprinted breast tumor-stroma models for pre-clinical drug testing[J]. Mater Today Bio, 2023, 23: 100826. DOI: 10.1016/j.mtbio.2023.100826 . |
| [33] | DUAN J H, CAO Y Y, SHEN Z Z, et al. 3D bioprinted GelMA/PEGDA hybrid scaffold for establishing an in vitro model of melanoma[J]. J Microbiol Biotechnol, 2022, 32(4): 531-540. DOI: 10.4014/jmb.2111.11003 . |
| [34] | BLAESER A, DUARTE CAMPOS D F, FISCHER H. 3D bioprinting of cell-laden hydrogels for advanced tissue engineering[J]. Curr Opin Biomed Eng, 2017, 2: 58-66. DOI: 10.1016/j.cobme.2017.04.003 . |
| [35] | CHOI K Y, AJITERU O, HONG H, et al. A digital light processing 3D-printed artificial skin model and full-thickness wound models using silk fibroin bioink[J]. Acta Biomater, 2023, 164: 159-174. DOI: 10.1016/j.actbio.2023.04.034 . |
| [36] | FU H J, ZHANG D Q, ZENG J S, et al. Application of 3D-printed tissue-engineered skin substitute using innovative biomaterial loaded with human adipose-derived stem cells in wound healing[J]. Int J Bioprint, 2023, 9(2): 674. DOI: 10.18063/ijb.v9i2.674 . |
| [37] | LIU H, WANG C, SUN X Q, et al. Silk fibroin/collagen/hydroxyapatite scaffolds obtained by 3D printing technology and loaded with recombinant human erythropoietin in the reconstruction of alveolar bone defects[J]. ACS Biomater Sci Eng, 2022, 8(12): 5245-5256. DOI: 10.1021/acsbiomaterials.2c00690 . |
| [38] | CAI X B, XU Y Q, YU K F, et al. Clinical application of 3-dimensional printed navigation templates in treating femoral head osteonecrosis with pedicled iliac bone graft[J]. Ann Plast Surg, 2020, 84(5S ): S230-S234. DOI: 10.1097/SAP.0000000000002362 . |
| [39] | PALIWAL A, JAIN S, KUMAR S, et al. Predictive Modelling in pharmacokinetics: from in-silico simulations to personalized medicine[J]. Expert Opin Drug Metab Toxicol, 2024, 20(4): 181-195. DOI: 10.1080/17425255.2024.2330666 . |
| [40] | MADDEN J C, ENOCH S J, PAINI A, et al. A review of in silico tools as alternatives to animal testing: principles, resources and applications[J]. Altern Lab Anim, 2020, 48(4): 146-172. DOI: 10.1177/0261192920965977 . |
| [41] | SILVA A C, BORBA J V V B, ALVES V M, et al. Novel computational models offer alternatives to animal testing for assessing eye irritation and corrosion potential of chemicals[J]. Artif Intell Life Sci, 2021, 1: 100028. DOI: 10.1016/j.ailsci.2021.100028 . |
| [42] | CHOU W C, CHENG Y H, RIVIERE J E, et al. Development of a multi-route physiologically based pharmacokinetic (PBPK) model for nanomaterials: a comparison between a traditional versus a new route-specific approach using gold nanoparticles in rats[J]. Part Fibre Toxicol, 2022, 19(1): 47. DOI: 10.1186/s12989-022-00489-4 . |
| [43] | LI T, ROBERTS R, LIU Z C, et al. TransOrGAN: an artificial intelligence mapping of rat transcriptomic profiles between organs, ages, and sexes[J]. Chem Res Toxicol, 2023, 36(6): 916-925. |
| [44] | CHEN X, ROBERTS R, LIU Z C, et al. A generative adversarial network model alternative to animal studies for clinical pathology assessment[J]. Nat Commun, 2023, 14(1): 7141. DOI: 10.1038/s41467-023-42933-9 . |
| [45] | SHARUN K, BANU S A, MAMACHAN M, et al. Development and characterization of contraction-suppressed full-thickness skin wound model in rabbits[J]. Tissue Cell, 2024, 90: 102482. DOI: 10.1016/j.tice.2024.102482 . |
| [46] | KATOH M, HAMAJIMA F, OGASAWARA T, et al. Assessment of the human epidermal model LabCyte EPI-MODEL for in vitro skin corrosion testing according to the OECD test guideline 431[J]. J Toxicol Sci, 2010, 35(3): 411-417. DOI: 10.2131/jts.35.411 . |
| [47] | OECD2010. Guidelines for the Testing of Chemicals, No.439:In Vitro Skin Imitation Reconstructed Human Epidemnis Test Method [S]. Paris, France:OECD. |
| [48] | HARTUNG T. Making big sense from big data in toxicology by read-across[J]. Altex, 2016: 83-93. DOI: 10.14573/altex.1603091 . |
| [49] | MURATA Y, NEUHOFF S, ROSTAMI-HODJEGAN A, et al. In vitro to in vivo extrapolation linked to physiologically based pharmacokinetic models for assessing the brain drug disposition[J]. AAPS J, 2022, 24(1): 28. DOI: 10.1208/s12248-021-00675-w . |
| [50] | DARWISH M, MARBURY T C, NUNEZ R, et al. Physiologically-based pharmacokinetic modeling of trofinetide in moderate renal impairment for phase 1 clinical study dose selection with model validation[J]. Eur J Drug Metab Pharmacokinet, 2025, 50(1): 23-38. DOI: 10.1007/s13318-024-00924-1 . |
| [51] | DIETERLE F, SISTARE F, GOODSAID F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium[J]. Nat Biotechnol, 2010, 28(5): 455-462. DOI: 10.1038/nbt.1625 . |
| [52] | KADYROV J, SALA S, GRIGOROFF L, et al. A clinical chemical atlas of xenobiotic toxicity for the Sprague–Dawley rat[J]. Arch Toxicol, 2025, 99(6): 2669-2681. DOI: 10.1007/s00204-025-04008-0 . |
| [1] | TAN Dengxu, MA Yifan, LIU Ke, ZHANG Yanying, SHI Changhong. Reshaping Intercellular Interactions: Empowering the Exploration of Disease Mechanisms and Therapies Using Organoid Co-Culture Models [J]. Laboratory Animal and Comparative Medicine, 2025, 45(3): 309-317. |
| [2] | Yinghan WAN, Yexin GU, Yunong YUAN, Min TANG, Li LU. Implications on the Development of Animal Disease Models from FDA Modernization Act 2.0 [J]. Laboratory Animal and Comparative Medicine, 2023, 43(5): 472-481. |
| [3] | CHEN Xiaojuan, LI Wei, WANG Lie. Exploration on Informatization of Laboratory Animal Management Process in Colleges and Universities: The Case of Zhejiang University [J]. Laboratory Animal and Comparative Medicine, 2021, 41(6): 554-558. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||